Speakers - CRDWC 2025

Biography

Silvia Fenoglio is a principal scientist in functional genomics at Tango Therapeutics, focusing on target identification and validation.  Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. 

Silvia Fenoglio completed a PhD in genetics at Cold Spring Harbor Laboratory working on in vivo high throughput shRNA screening in syngeneic models and hit validation. Throughout her career, her interests always orbited around functional genomics applications in oncology preclinical models.